The Fort Worth Press - Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

USD -
AED 3.673042
AFN 65.000368
ALL 82.122238
AMD 360.540403
ANG 1.790403
AOA 917.000367
ARS 1543.709041
AUD 1.475634
AWG 1.8015
AZN 1.70397
BAM 1.769883
BBD 2.014669
BDT 124.411223
BGN 1.773403
BHD 0.377343
BIF 3003.542682
BMD 1
BND 1.287984
BOB 11.678099
BRL 5.641895
BSD 1.000231
BTN 94.214794
BWP 13.981141
BYN 2.99667
BYR 19600
BZD 2.011773
CAD 1.426225
CDF 2315.000362
CHF 0.83934
CLF 0.025291
CLP 995.370396
CNY 6.67065
CNH 6.673715
COP 3329.7
CRC 448.217041
CUC 1
CUP 24.005936
CVE 99.783267
CZK 22.12495
DJF 177.720393
DKK 6.77732
DOP 60.847375
DZD 136.97204
EGP 53.41704
ERN 15
ETB 164.172805
EUR 0.90663
FJD 2.27435
FKP 0.755319
GBP 0.757055
GEL 2.590391
GGP 0.755319
GHS 11.72787
GIP 0.755319
GMD 74.000355
GNF 8862.08254
GTQ 7.646644
GYD 209.264655
HKD 7.845475
HNL 26.897304
HRK 6.831741
HTG 131.169348
HUF 330.483504
IDR 18244.35
ILS 3.216704
IMP 0.755319
INR 94.28655
IQD 1516.38825
IRR 1913500.000352
ISK 123.850386
JEP 0.755319
JMD 158.047862
JOD 0.70904
JPY 159.847504
KES 129.920385
KGS 87.435504
KHR 4109.279134
KMF 446.00035
KPW 900.00035
KRW 1336.585039
KWD 0.31149
KYD 0.833529
KZT 445.849094
LAK 22515.825147
LBP 89572.5119
LKR 332.687818
LRD 170.045065
LSL 16.909851
LTL 2.95274
LVL 0.60489
LYD 6.447585
MAD 9.910789
MDL 18.169149
MGA 4544.611305
MKD 55.788429
MMK 2099.899875
MNT 3604.081637
MOP 8.083632
MRU 40.453556
MUR 47.620378
MVR 15.410378
MWK 1734.475956
MXN 18.55962
MYR 4.086104
MZN 63.910377
NAD 16.909928
NGN 1346.880377
NIO 36.812314
NOK 9.57034
NPR 150.739077
NZD 1.80993
OMR 0.384492
PAB 1.000231
PEN 3.403481
PGK 4.56452
PHP 63.906504
PKR 276.594484
PLN 3.995035
PYG 6207.891986
QAR 3.646367
RON 4.849704
RSD 106.668038
RUB 82.702274
RWF 1479.82915
SAR 3.768617
SBD 8.097299
SCR 13.914518
SDG 601.503676
SEK 10.07658
SGD 1.28826
SHP 0.749316
SLE 22.903667
SLL 20969.503664
SOS 571.625064
SRD 37.49037
STD 20697.981008
STN 22.171043
SVC 8.752585
SYP 13002.000337
SZL 16.904964
THB 33.901504
TJS 9.227282
TMT 3.51
TND 3.015171
TOP 2.40776
TRY 50.36547
TTD 6.789769
TWD 32.893038
TZS 2648.920367
UAH 45.477786
UGX 4131.053487
UYU 40.541335
UZS 12028.469429
VES 900.490504
VND 25725.5
VUV 120.332725
WST 2.794859
XAF 594.710569
XAG 0.020369
XAU 0.000257520566
XCD 2.70255
XCG 1.802699
XDR 0.707052
XOF 594.710569
XPF 107.923207
YER 236.503589
ZAR 16.932805
ZMK 9001.203584
ZMW 20.450473
ZWL 321.999592
SSP 5946.510642
MXV 2.084268
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera  Prototype Ahead of Full-Scale Development
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds.

Text size:

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.

"Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach."

Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera.

Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-solutionspr/

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies Inc.
[email protected]

SOURCE: Avant Solutions



View the original press release on ACCESS Newswire

W.Matthews--TFWP